Protagonist Therapeutics Inc. (PTGX) last year’s performance of -56.70% is a clear signal for an entertaining trading season.

Protagonist Therapeutics Inc. (NASDAQ: PTGX) kicked off on January 24, 2023, at the price of $11.47, up 10.72% from the previous trading day. During the day, the shares moved up to $12.78 and dropped to $11.21 before settling in for the closing price of $11.47. Over the past 52 weeks, PTGX has traded in a range of $6.91-$30.42.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


While this was happening, its average annual earnings per share was recorded -40.90%. With a float of $48.48 million, this company’s outstanding shares have now reached $49.11 million.

The firm has a total of 122 workers. Let’s measure their productivity. In terms of profitability, gross margin is +89.86, operating margin of -471.34, and the pretax margin is -470.27.

Protagonist Therapeutics Inc. (PTGX) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Protagonist Therapeutics Inc. is 1.60%, while institutional ownership is 98.30%.

Protagonist Therapeutics Inc. (PTGX) Recent Fiscal highlights

In the latest quarterly report, which was put into the public domain on 6/29/2022, the organization reported -$0.84 earnings per share (EPS), higher than consensus estimate (set at -$0.93) by $0.09. This company achieved a net margin of -458.94 while generating a return on equity of -43.32. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.72 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -40.90% per share during the next fiscal year.

Protagonist Therapeutics Inc. (NASDAQ: PTGX) Trading Performance Indicators

Take a look at Protagonist Therapeutics Inc.’s (PTGX) current performance indicators. Last quarter, stock had a quick ratio of 7.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.01.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -3.02 in one year’s time.

Technical Analysis of Protagonist Therapeutics Inc. (PTGX)

Analysing the last 5-days average volume posted by the [Protagonist Therapeutics Inc., PTGX], we can find that recorded value of 1.05 million was better than the volume posted last year of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 38.60%. Additionally, its Average True Range was 0.71.

During the past 100 days, Protagonist Therapeutics Inc.’s (PTGX) raw stochastic average was set at 93.02%, which indicates a significant increase from 83.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.12% in the past 14 days, which was higher than the 59.81% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $9.55, while its 200-day Moving Average is $9.82. Now, the first resistance to watch is $13.25. This is followed by the second major resistance level at $13.80. The third major resistance level sits at $14.82. If the price goes on to break the first support level at $11.68, it is likely to go to the next support level at $10.66. Now, if the price goes above the second support level, the third support stands at $10.11.

Protagonist Therapeutics Inc. (NASDAQ: PTGX) Key Stats

The company with the Market Capitalisation of 633.86 million has total of 49,198K Shares Outstanding. Its annual sales at the moment are 27,360 K in contrast with the sum of -125,550 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -31,230 K.


On What Basis Did Swvl Holdings Corp (SWVL) Stock Rise 47% Pre-Hours?

When last checked, Swvl Holdings Corp. (Nasdaq: SWVL), a...

What Drove Organovo (ONVO) Stock Up 15% In After-Hour Session On Tuesday?

Shares of Organovo Holdings Inc. (Nasdaq: ONVO) were up...

Is There Any Reason As To Why The Zai Lab (ZLAB) Stock Expanded By 13%?

The biopharmaceutical business Zai Lab Limited (NASDAQ: ZLAB), which...



Don't miss

Wearable Devices (WLDS) Stock Rose 12% On Tuesday, But On What Basis?

Wearable Devices Ltd (NASD: WLDS) is experiencing significant growth...

Did Anything Boost ObsEva (OBSV) Stock In Pre-Hours Trading?

Following an update, shares of ObsEva SA (NASD: OBSV)...

How Did The Kalera (KAL) Stock Rise 32% Pre-Hours?

At the time of the most recent check, shares...

Why Has Selina Hospitality (SLNA) Stock Increased In Extended Session On Friday?

The stock of Selina Hospitality PLC (NASD: SLNA), which...

Do You Know Why Evolv Technologies (EVLV) Stock Surged Nearly 10% Today?

Today's charts show Evolv Technologies Holdings Inc. (Nasdaq: EVLV)...

Cronos Group Inc. (CRON) poses a Brand-New Opportunity for Investors with beta value of 1.31

Cronos Group Inc. (NASDAQ: CRON) open the trading on February 02, 2023, with great promise as it jumped 2.79% to $2.58. During the day,...

Rite Aid Corporation (RAD) volume hits 3.98 million: A New Opening for Investors

Witnessing the stock’s movement on the chart, on February 02, 2023, Rite Aid Corporation (NYSE: RAD) set off with pace as it heaved 3.52%...

Cano Health Inc. (CANO) volume hits 6.34 million: A New Opening for Investors

Cano Health Inc. (NYSE: CANO) flaunted slowness of -1.44% at $1.37, as the Stock market unbolted on February 02, 2023. During the day, the...


Please enter your comment!
Please enter your name here